UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
Brief description of study
Request for collaborative review: WIRB serving as IRB of record.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Cancer', 'Non Small Cell Lung Cancer Metastatic', 'Metastatic Melanoma', 'Neoplasm of Lung', 'Melanoma
-
Age: - 99 Years
-
Gender: All
Updated on
30 Jan 2020.
Study ID: 827441
